Lercanidipine Hcl Double-E Pharma

Lercanidipine hydrochloride, the active ingredient in Lercanidipine HCl Double-E Pharma, is a dihydropyridine calcium channel blocker presented as an oral formulation for systemic use. It is used to treat essential hypertension in adult patients. GNH USA supplies Lercanidipine HCl Double-E Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for conditions within the hypertension disease family and works by lowering elevated blood pressure.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Secondary hypertension: can be added to other agents when blood pressure remains uncontrolled due to identifiable causes. Hypertension in elderly patients: helps achieve target blood pressure in older adults with age‑related vascular stiffness.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, usually on the face or neck. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeats.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or airway requiring urgent care. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, itching, or anaphylaxis. - Life‑threatening arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for safety concerns. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Heart failure: monitor for worsening symptoms due to fluid retention. - Pregnancy Category C: discuss potential risks and benefits with the patient. - Breastfeeding: consider potential exposure to the infant. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels. - Concomitant use with other potent antihypertensives: may cause additive hypotension. - Grapefruit juice: markedly raises drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: observe for bradycardia or excessive blood pressure lowering. - NSAIDs: may blunt antihypertensive response. - Alcohol: can enhance dizziness and hypotensive effects.